Dr Yip Pui Lam is an Associate Consultant at NCIS, specialising in Radiation Oncology, with a particular interest in nasopharyngeal carcinoma and head and neck cancers. She trained and practiced in Hong Kong, where she completed her Clinical Oncology specialist training.
With a solid foundation in Clinical Oncology, Dr Yip advocates for individualised treatment approaches, recognising that effective cancer care must be tailored to each patient's unique needs. She earned her bachelor's degree in psychology and graduated with honors from the Chinese University of Hong Kong with her medical degree in 2014. She became a Fellow of the Royal College of Radiologists (UK) in 2019 and subsequently completed her fellowship with the Hong Kong College of Radiologists and the Hong Kong Academy of Medicine in 2022. She has also been honoured with the Frank Doyle Medal and the Gold Award in recognition of her academic achievements.
Dr Yip is dedicated to advancing the understanding and management of head and neck cancers. Her research integrates clinical practice with a focus on radiotherapy techniques and individualised treatment strategies, emphasising the optimisation of patient outcomes and the reduction of treatment toxicity. Her publication record in high-impact medical journals reflects her commitment to bridging the gap between research and clinical practice. Dr Yip also actively participates in international oncology groups, serving as a committee member for the Head and Neck Cancer International Group, where she collaborates enthusiastically with researchers and clinicians worldwide to enhance cancer care.
1. Lee S F, Kennedy S K F, Caini S, Wong H C Y, Yip P L, Poortmans P M et al. Randomised controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis BMJ 2024; 386 :e079089 doi:10.1136/bmj-2023-079089
2. Yip, P. L., Zheng, H., Cheo, T., Tan, T. H., Lee, S. F., Leong, Y. H., Wong, L. C., Tey, J.,Ho, F., & Soon, Y. Y. (2024). Stroke Risk in Survivors of Head and Neck Cancer. JAMA network open, 7(2), e2354947. doi.org/10.1001/jamanetworkopen.2023.54947
3. Wang, X., Huang, N., Yip, PL., Wang, J., Huang, R., Sun, Z., Kang, D., He, Q., Deng, X., Zhao, C., Chua, M. L. K., & Han, F. (2024). The individualized delineation of clinical target volume for primary nasopharyngeal carcinoma based on invasion risk of substructures: a prospective, real-word study with a large population. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 110154. Advance online publication. doi.org/10.1016/j.radonc.2024.110154
4. Yip, P. L., You, R., Chen, M. Y., & Chua, M. L. K. (2024). Embracing Personalized Strategies in Radiotherapy for Nasopharyngeal Carcinoma: Beyond the Conventional Bounds of Fields and Borders. Cancers, 16(2), 383. doi.org/10.3390/cancers16020383
5. Neo J, Yip PL, Ong EHW, et al. Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma. Oral Oncol. Published online December 5, 2023. doi:10.1016/j.oraloncology.2023.106655
6. Yip, P. L., Lee, W. Y. V., Leung, W. K., Nyaw, S. F., Chan, N. Y., & Lee, S. F. (2023). Stereotactic Body Radiation Therapy to the Foot for Bone Metastasis. Advances in radiation oncology, 9(2), 101363. doi.org/10.1016/j.adro.2023.101363
7. Yip PL, Lee AWM, Chua MLK. Adjuvant chemotherapy in nasopharyngeal carcinoma. Lancet Oncol. 2023;24(7):713-715. doi:10.1016/S1470-2045(23)00266-8
8. Yip PL, Fung WHB, Lee FAS, Lee CF, Wong NSM, Lee SF. Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer. Front Oncol. 2023;13:1138357. Published 2023 Apr 6. doi:10.3389/fonc.2023.1138357
9. Lee SF, Yip PL, Chan OL, Lee VWY, Wong A, Choi HCW. Brain Metastasis Growth Kinetics: A Novel Prognosticator for Stereotactic Radiotherapy. Clin Oncol (R Coll Radiol). 2023;35(5):e328-e335. doi:10.1016/j.clon.2023.02.012
10. Lee SF, Yip PL, Wong A, et al. Splenic irradiation contributes to grade ≥ 3 lymphopenia after adjuvant chemoradiation for stomach cancer. Clin Transl Radiat Oncol. 2022;36:83-90. Published 2022 Jul 21. doi:10.1016/j.ctro.2022.07.007
